Kerecis ehf (Kerecis) operates as a medical device company that provides products that treat chronic wounds and damaged tissue. The company’s flagship product includes Kerecis Omega3 fish-skin acellular dermal matrix transplantation technology is intended for use in products to treat acute, chronic, and oral wounds, for dura mater repair, breast reconstruction, and abdominal wall reconstruction, and for surgical stapling. It also develops mOmega3 fatty acid (fish-sourced fatty acids) technology for use in several dermatological indications such as psoriasis, eczema, dermatitis, keratosis pilaris, and pseudofolliculitis. Kerecis also provides fish-skin acellular dermal matrix products including Omega3 Wound, Omega3 Dura, Omega3 Hernia, Omega3 Pectus, Omega3 Seal, and topical creams including Smooth with mOmega3, Footguard with mOmega3, Psoria with mOmega3 and Xma with mOmega3. The company uses complete acellular fish skin for tissue regeneration by transplantation. Kerecis is headquartered in Isafjordur, Iceland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Kerecis ehf
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Kerecis ehf Company Overview
- Kerecis ehf Company Snapshot
- Kerecis ehf Pipeline Products and Ongoing Clinical Trials Overview
- Kerecis ehf - Pipeline Analysis Overview
- Kerecis ehf - Key Facts
- Kerecis ehf - Major Products and Services
- Kerecis ehf Pipeline Products by Development Stage
- Kerecis ehf Ongoing Clinical Trials by Trial Status
- Kerecis ehf Pipeline Products Overview
- Kerecis Omega3 - Battlefield Wounds
- Kerecis Omega3 - Battlefield Wounds Product Overview
- Kerecis Omega3 - Third-Degree Burns
- Kerecis Omega3 - Third-Degree Burns Product Overview
- Kerecis Omega3 Dura
- Kerecis Omega3 Dura Product Overview
- Kerecis Omega3 Hernia
- Kerecis Omega3 Hernia Product Overview
- Kerecis Omega3 Viruxide System
- Kerecis Omega3 Viruxide System Product Overview
- Kerecis Omega3 Viruxide System Clinical Trial
- Kerecis ehf - Key Competitors
- Kerecis ehf - Key Employees
- Kerecis ehf - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Kerecis ehf, Recent Developments
- Nov 06, 2019: Peer-Reviewed Article in “Wounds” Examines Efficacy of Kerecis Fish Skin Treatment for Diabetic Foot Wounds
- Oct 11, 2019: Medical fish skin company Kerecis presents new research at the Symposium on Advanced Wound Care
- Aug 05, 2019: Former President of Iceland joins the Board of Kerecis, the Medical Fish Skin Company
- May 07, 2019: New research on the Kerecis Fish-Skin-Grafts wound treatment to be presented at the Symposium on Advanced Wound Care
- Apr 30, 2019: Dr. Michael J. Lacqua on the benefits of the Kerecis Omega3 technology
- Apr 01, 2019: Clinical study finds burn patients treated with Kerecis Omega3 intact fish skin experienced pain relief, fast healing and no infections
- Jan 25, 2019: Kerecis hires Stephen DiBiasio as Executive Vice President
- Dec 05, 2018: Phytoceuticals receives marketing approval in Australia
- Nov 27, 2018: MedStar Health to initiate an IDE Feasibility Trial on full-thickness burn wounds treated with Kerecis omega3 intact fish skin
- Nov 02, 2018: Double-blind clinical trial finds treatment with EpiFix Was 76% more expensive than Kerecis Omega3
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Kerecis ehf Pipeline Products and Ongoing Clinical Trials Overview
- Kerecis ehf Pipeline Products by Equipment Type
- Kerecis ehf Pipeline Products by Indication
- Kerecis ehf Ongoing Clinical Trials by Trial Status
- Kerecis ehf, Key Facts
- Kerecis ehf, Major Products and Services
- Kerecis ehf Number of Pipeline Products by Development Stage
- Kerecis ehf Pipeline Products Summary by Development Stage
- Kerecis ehf Ongoing Clinical Trials by Trial Status
- Kerecis ehf Ongoing Clinical Trials Summary
- Kerecis Omega3 - Battlefield Wounds - Product Status
- Kerecis Omega3 - Battlefield Wounds - Product Description
- Kerecis Omega3 - Third-Degree Burns - Product Status
- Kerecis Omega3 - Third-Degree Burns - Product Description
- Kerecis Omega3 Dura - Product Status
- Kerecis Omega3 Dura - Product Description
- Kerecis Omega3 Hernia - Product Status
- Kerecis Omega3 Hernia - Product Description
- Kerecis Omega3 Viruxide System - Product Status
- Kerecis Omega3 Viruxide System - Product Description
- Kerecis Omega3 Viruxide System - Study Evaluate the Efficacy of Kerecis Omega3 Viruxide System in COVID-19 Subjects
- Kerecis ehf, Key Employees
- Kerecis ehf, Other Locations
- Kerecis ehf, Subsidiaries
- Glossary
- Kerecis ehf Pipeline Products by Equipment Type
- Kerecis ehf Pipeline Products by Development Stage
- Kerecis ehf Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ossur hf
- TeamOlmed AB
- Ossur Nordic, AB
- TeamOlmed AB
- Ossur hf
- Ossur Nordic, AB
